Topic: Private Equity Firm
Ian Read is taking on an operating executive job at Carlyle, just as Robert Essner became a senior adviser at the PE firm after retiring from Wyeth.
The private equity investment values Biocon's biosimilar unit at $3 billion, just three times its target $1 billion revenues in fiscal 2022.
Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.
Private equity player Ampersand Capital Partners is backing another CDMO, this one targeted at sterile injectables.
Known for aggressive acquisitions of its own, CDMO Cambrex is now the target of a buyout bid—this time to the tune of $2 billion.
Bayer’s for-sale animal health unit has been stirring up interest among private equity players—but the company may have another buyer in mind.
Private equity players are buzzing around Bayer's animal health unit as the German conglomerate seeks buyers—and the €8 billion a deal could generate.
Just weeks after selling its share in Brammer Bio in a $1.7 billion deal, Ampersand has an agreement to buy another CDMO with viral vector expertise.
Bayer's sale of its animal health unit is attracting interest from a wide variety of players, including private equity firms and even rivals, a new report reveals.
When Mylan said last month that it would consider a sale, analysts were skeptical the company could find an interested buyer.